AIM
LXRX icon

Assured Investment Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Assured Investment Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-79,368
Closed -$611K – 496
2019
Q1 		$611K Buy
+79,368
New +$482K 0.01% 521

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Assured Investment Management's LXRX Position: Q2 2019 in Review

Assured Investment Management sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2019, closing a stake of 79,368 shares — an estimated $611K sold.

Assured Investment Management first reported a position in LXRX in Q1 2019 and held it in 1 quarter. The position peaked at $611K in Q1 2019. 109 funds tracked by Wall St. Rank hold LXRX as of Q2 2019.

  • Assured Investment Management reported no remaining Lexicon Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Assured Investment Management sold 79,368 Lexicon Pharmaceuticals shares in Q2 2019, an estimated $611K.
  • Assured Investment Management first reported a position in Lexicon Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Assured Investment Management's Lexicon Pharmaceuticals position peaked at $611K in Q1 2019.
  • 109 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2019.

Based on Assured Investment Management's 13F filing for Q2 2019, filed 14 Aug 2019.